Innovationsdag with Volker Lauschke, CEO of Hepapredict
This time about Microphysiological liver models – from academic research to commercial dissemination.
Get inspired and get some good advice from Volker Lauschke, CEO of Hepapredict.
HepaPredict AB is a contract research organization (CRO) specializing in drug metabolism and toxicity. They offer in-house evaluations of drug metabolism, pharmacokinetic properties and safety as well as drug target validations based on our novel long-term stable physiological 3D spheroid culture platform.
HepaPredict was founded in 2016 as a private spin-off from Karolinska Institutet. Their ambition is to commission their scientific experience and expertise to deliver highest-quality science with the goal to support and optimize drug development efficacy and safety.
InnovatiOnsdag a seminars series that will be organized by KI Innovations AB together with KICC (Karolinska Institutet Clinicum Connection) during Spring 2019. On Wednesdays between 16-17 over a light food and drinks, you will hear inspiring speakers tell about their entrepreneurial journey, the situation in Swedish life science industry or maybe learn how to pitch an idea.